EUVIMEDEUVIMED entdecken
Multizentrische Studie

Central pancreatectomy might be an acceptable surgical procedure for clinical T1 pancreatic body ductal adenocarcinoma: A multicenter retrospective analysis

Taichi Terai iD, Manabu Kawai, Yuji Kitahata, Sohei Satoi iD, Daisuke Hashimoto iD, Minako Nagai iD, Satoshi Nishiwada, Tomohisa Yamamoto, Hiroki Yamaue iD, Masayuki Sho iD

Journal of Hepato-Biliary-Pancreatic Sciences · 2023

DOI: 10.1002/jhbp.1355 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2023. Verfasst von Taichi Terai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Central pancreatectomy (CP) is accepted as a function‐preserving procedure for benign tumors. However, the indication of CP for pancreatic cancers is limited. This multicenter study aimed to clarify the indications of CP for clinical T1 pancreatic body cancer.

Methods

This multicenter study analyzed patients who underwent CP or distal pancreatectomy (DP) for clinical T1 pancreatic body cancer between 2013 and 2020 at three high‐volume centers.

Results

A total of 50 patients were enrolled: nine patients, who underwent CP, were classified into the CP group, while 38 patients, who underwent DP, served as controls. Three patients converted CP to DP during operation were excluded. Five patients in the CP group and 15 patients in the control group underwent preoperative treatment. The 5‐year survival rate was 100% in the CP group, and 42% ( p = .040) in the control group. Recurrence was found in three patients in the CP group. Importantly, insulin was not required after surgery in patients in the CP group.

Conclusion

The clinical outcomes of CP were comparable to or even better than that of conventional pancreatectomy. Our collaborative study suggests that CP may be an acceptable therapeutic option for selected patients with clinical T1 pancreatic body cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansPancreatectomyTreatment OutcomePancreasRetrospective StudiesPostoperative Complications

Stichwörter der Autor:innen

central pancreatectomymulticenter studyneoadjuvant therapyorgan preservationpancreatic body cancer

Autor:innen und Institutionen

  • Department of Surgery, Nara Medical University, Kashihara, Nara, Japan.
  • Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
  • Department of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
  • Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

ORCID-Profile: Taichi Terai, Sohei Satoi, Daisuke Hashimoto, Minako Nagai, Hiroki Yamaue, Masayuki Sho

Zitieren

APA

Terai, T., Kawai, M., Kitahata, Y., Satoi, S., Hashimoto, D., Nagai, M., Nishiwada, S., Yamamoto, T., Yamaue, H., & Sho, M. (2023). Central pancreatectomy might be an acceptable surgical procedure for clinical T1 pancreatic body ductal adenocarcinoma: A multicenter retrospective analysis. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.1355

Vancouver

Terai T, Kawai M, Kitahata Y, Satoi S, Hashimoto D, Nagai M, et al. Central pancreatectomy might be an acceptable surgical procedure for clinical T1 pancreatic body ductal adenocarcinoma: A multicenter retrospective analysis. Journal of Hepato-Biliary-Pancreatic Sciences. 2023. doi:10.1002/jhbp.1355

BibTeX
@article{Terai2023,
  author = {Terai, Taichi and Kawai, Manabu and Kitahata, Yuji and Satoi, Sohei and Hashimoto, Daisuke and Nagai, Minako and Nishiwada, Satoshi and Yamamoto, Tomohisa and Yamaue, Hiroki and Sho, Masayuki},
  title = {Central pancreatectomy might be an acceptable surgical procedure for clinical T1 pancreatic body ductal adenocarcinoma: A multicenter retrospective analysis},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2023},
  doi = {10.1002/jhbp.1355}
}
Kostenlos starten →